Grown Rogue International (GRUSF) Non Operating Investment Income (2011 - 2025)
Grown Rogue International's (GRUSF) quarterly Non Operating Investment Income came in at $234.4 billion in Q3 2025, up 148.05% year-on-year from $94.5 billion in Q3 2024, and down 51.95% quarter-over-quarter from $487.9 billion in Q4 2024.
Grown Rogue International (GRUSF) Non Operating Investment Income (2011 - 2025) Analysis & Trends
Grown Rogue International's Non Operating Investment Income history runs 13 years deep, the most recent figure standing at $234.4 billion for Q3 2025.
- On a quarterly basis, Non Operating Investment Income rose 148.05% year-over-year to $234.4 billion in Q3 2025; TTM through Sep 2025 was $234.4 billion, a 148.05% increase from a year earlier, with the FY2024 full-year figure at -$50057.0, down 157.08% from the prior year.
- Non Operating Investment Income fell to $234.4 billion in Q3 2025 per GRUSF's latest filing, from $487.9 billion in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $487.9 billion in Q4 2024 and bottomed at -$487.9 billion in Q3 2024.
- The 5-year median for Non Operating Investment Income is -$114241.0 (2021), against an average of $16.7 billion.
- Across the five-year window, Non Operating Investment Income sank 2590.3% in 2023 and surged 556322350.03% in 2024, its largest moves.
- Year by year, Non Operating Investment Income stood at -$140783.0 in 2021, then surged by 95.56% to -$6250.0 in 2022, then tumbled by 1303.18% to -$87699.0 in 2023, then jumped by 556322350.03% to $487.9 billion in 2024, then tumbled by 51.95% to $234.4 billion in 2025.
- Per Business Quant, the three latest GRUSF Non Operating Investment Income figures stand at $234.4 billion (Q3 2025), $487.9 billion (Q4 2024), and -$487.9 billion (Q3 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.32 Mn | 85.61 Mn | 3.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 234.44 Bn |
| Sep 30, 2025 | 234.44 Bn |
| Dec 31, 2024 | 487.89 Bn |
| Dec 31, 2024 | 487.89 Bn |
| Sep 30, 2024 | -487.89 Bn |
| Sep 30, 2024 | -487.89 Bn |
| Jun 30, 2024 | -5.52 Mn |
| Jun 30, 2024 | -5.52 Mn |
| Mar 31, 2024 | -2,177.00 |
| Mar 31, 2024 | -2,177.00 |
| Dec 31, 2023 | -87,699.00 |
| Dec 31, 2023 | -87,699.00 |
| Oct 31, 2023 | -4.63 Mn |
| Oct 31, 2023 | -4.63 Mn |
| Jul 31, 2023 | -743,682.00 |
| Jul 31, 2023 | -743,682.00 |
| Jan 31, 2023 | -168,144.00 |
| Jan 31, 2023 | -168,144.00 |
| Jan 31, 2022 | -6,250.00 |
| Jan 31, 2022 | -6,250.00 |